TP-021
CAS No. : 2130878-25-8
(Synonyms: BCL6-IN-8c)
| Size | Price | Stock |
|---|---|---|
| 5mg | $220 | In-stock |
| 10mg | $350 | In-stock |
| 25mg | $690 | In-stock |
| 50mg | $1100 | In-stock |
| 100mg | $1800 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-119402 |
| M.Wt: | 417.84 |
| Formula: | C20H20ClN3O5 |
| Purity: | >98 % |
| Solubility: | DMSO : ≥ 50 mg/mL |
TP-021 (BCL6-IN-8c) is a potent and orally active B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor with an IC50 of 0.10 μM in cell-free enzyme-linked immunosorbent assay[1]. IC50 & Target:IC50: 0.10 μM (BCL6-corepressor interaction)[1] In Vitro:TP-021 (BCL6-IN-8c, Compound 8c) also exhibits good cellular PPI inhibitory activity in the submicromolar range (M2H IC50 = 0.72 μM). TP-021 (BCL6-IN-8c) does not exhibit significant cytotoxicity even at 30 μM[1]. In Vivo:The pharmacokinetic profile of TP-021 (BCL6-IN-8c, Compound 8c) is evaluated by a mouse cassette-dosing study (0.1 mg/kg iv; 1 mg/kg po). TP-021 (BCL6-IN-8c) exhibits a good pharmacokinetic profile (Cmax = 233 ng/mL, Tmax = 2 hours, MRT = 3.3 h, AUC = 1.27 mg?h/mL, F (oral bioavailability) = 79.9%)[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- TP-021
- Cat. No.:
- HY-119402
- Quantity:
Your information is safe with us.